EP3405191A4 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERHIDROSIS - Google Patents

METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERHIDROSIS Download PDF

Info

Publication number
EP3405191A4
EP3405191A4 EP16886713.3A EP16886713A EP3405191A4 EP 3405191 A4 EP3405191 A4 EP 3405191A4 EP 16886713 A EP16886713 A EP 16886713A EP 3405191 A4 EP3405191 A4 EP 3405191A4
Authority
EP
European Patent Office
Prior art keywords
hyperhidrosis
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16886713.3A
Other languages
German (de)
French (fr)
Other versions
EP3405191B1 (en
EP3405191A1 (en
Inventor
Benjamin F. MCGRAW III
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravida Inc
Original Assignee
Theravida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravida Inc filed Critical Theravida Inc
Publication of EP3405191A1 publication Critical patent/EP3405191A1/en
Publication of EP3405191A4 publication Critical patent/EP3405191A4/en
Application granted granted Critical
Publication of EP3405191B1 publication Critical patent/EP3405191B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
EP16886713.3A 2016-01-20 2016-01-20 Compositions for use in treating hyperhidrosis Active EP3405191B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/014150 WO2017127073A1 (en) 2016-01-20 2016-01-20 Methods and compositions for treating hyperhidrosis

Publications (3)

Publication Number Publication Date
EP3405191A1 EP3405191A1 (en) 2018-11-28
EP3405191A4 true EP3405191A4 (en) 2019-09-04
EP3405191B1 EP3405191B1 (en) 2025-02-19

Family

ID=59314209

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16886713.3A Active EP3405191B1 (en) 2016-01-20 2016-01-20 Compositions for use in treating hyperhidrosis

Country Status (15)

Country Link
US (4) US10328057B2 (en)
EP (1) EP3405191B1 (en)
JP (1) JP6841834B2 (en)
KR (2) KR102600541B1 (en)
CN (1) CN108697688A (en)
AU (2) AU2016388308B2 (en)
BR (1) BR112018014661A2 (en)
CA (1) CA3011683C (en)
DK (1) DK3405191T3 (en)
HK (1) HK1258825A1 (en)
MX (1) MX394356B (en)
RU (1) RU2718906C2 (en)
TW (2) TW202341976A (en)
WO (1) WO2017127073A1 (en)
ZA (1) ZA201805490B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3061821T (en) 2009-07-22 2019-09-05 PureTech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis
KR102408292B1 (en) 2018-09-28 2022-06-10 카루나 세러퓨틱스 인코포레이티드 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
EP3993646B1 (en) 2019-07-05 2023-08-16 Swedish Match North Europe AB An oral pouched nicotine product including a filling material comprising nicotine-containing particles
PL4115746T3 (en) 2019-11-20 2024-01-29 Swedish Match North Europe Ab An oral pouched nicotine product including a filling material comprising nicotine particles
EP3967311A1 (en) * 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth
EP4018849B1 (en) 2020-12-22 2024-10-23 Swedish Match North Europe AB A pouched product for oral use
PL4018848T3 (en) 2020-12-22 2024-11-25 Swedish Match North Europe Ab A pouched product for oral use comprising a liquid permeable cover material and a filling material
EP4018847B1 (en) 2020-12-22 2024-09-18 Swedish Match North Europe AB A pouched product for oral use
CA3228464A1 (en) * 2021-08-11 2023-02-16 Theravida, Inc. Pharmaceutical compositions and methods for treating hyperhidrosis
TR2023000985A2 (en) * 2023-01-27 2023-02-21 Ardi Farma Ilac Pazarlama Ticaret Ltd Sirketi FORMULATION OF PROPIVERINE PROVIDING CONTROLLED RELEASE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110244051A1 (en) * 2010-04-01 2011-10-06 Theravida, Inc. Pharmaceutical formulations for the treatment of overactive bladder

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209505A (en) 1979-04-03 1980-06-24 Mikhail Adib R Pilocarpine mouthwash for dry mouth relief
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
SE450087B (en) 1985-10-11 1987-06-09 Haessle Ab GRAINS WITH CONTROLLED RELEASE OF PHARMACIFICALLY ACTIVE SUBSTANCES APPLIED SIGNED ON A COMPACT INSULABLE NUCLEAR MATERIAL
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
EP0746310B1 (en) 1994-02-23 1998-11-18 BM Research A/S Controlled release composition
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
EP0951279A1 (en) 1997-01-10 1999-10-27 Abbott Laboratories Tablet for the controlled release of active agents
JP3608800B2 (en) * 1997-03-26 2005-01-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pellet with core coated with antifungal agent and polymer
EP1041987B1 (en) 1997-12-22 2006-04-19 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa A method of preventing abuse of opioid dosage forms
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
EP1125586A4 (en) 1998-10-26 2003-06-11 Tanabe Seiyaku Co EXTENDED RELEASE PARTICLES
FR2795962B1 (en) 1999-07-08 2003-05-09 Prographarm Laboratoires PROCESS FOR THE MANUFACTURE OF MASK TASTE COATED GRANULES AND IMMEDIATE RELEASE OF THE ACTIVE INGREDIENT
CN100391438C (en) 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 Method for preparing aqueous coated pellets
NZ518309A (en) 1999-11-11 2003-05-30 Pharmacia Ab Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE60322371D1 (en) 2002-03-29 2008-09-04 Alza Corp VOLUME-SAVING MEDICINE FOR CONTROLLED RELEASE
FR2842736B1 (en) 2002-07-26 2005-07-22 Flamel Tech Sa ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF A PLURALITY OF MICROCAPSULES FOR PROLONGED RELEASE OF LOW SOLUBLE ACTIVE (S) PRINCIPLE (S)
FR2842735B1 (en) 2002-07-26 2006-01-06 Flamel Tech Sa MODIFIED RELEASE MICROCAPSULES OF LOW SOLUBLE ACTIVE PRINCIPLES FOR PER OS ADMINISTRATION
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
EP1635795A1 (en) 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
WO2005013939A1 (en) 2003-08-06 2005-02-17 Nirmal Mulye Pharmaceutical composition containing water soluble drug
DK2210605T3 (en) 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
CA2579767A1 (en) 2004-04-30 2005-11-10 Astellas Pharma Inc. Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
US20080254115A1 (en) 2004-05-19 2008-10-16 Rubino Orapin P Micropellet Containing Pellets and Method of Preparing Such Pellets
US20070224269A1 (en) 2004-06-10 2007-09-27 Rubino Orapin P Controlled Release Pharmaceutical Formulation
JP2008516893A (en) 2004-08-27 2008-05-22 スフェリックス，インク． Multilayer tablets and bioadhesive dosage forms
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2006132196A1 (en) 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation NOVEL PHARMACEUTICAL COMPRISING β3 AGONIST
ES2365161T3 (en) 2005-09-02 2011-09-23 Theravida, Inc. THERAPY FOR THE TREATMENT OF HYPERACTIVE BLADDER.
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20070077300A1 (en) 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
CN101340884A (en) * 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 Method for treating hyperhidrosis
US20100086592A1 (en) 2007-03-29 2010-04-08 Panacea Biotec Limited. Modified dosage forms of tacrolimus
US7563508B2 (en) 2007-05-30 2009-07-21 Chung Shan Institute Of Science And Technology, Armaments Bureau, M.N.D. Diffusion beads with core-shell structure
EP2173329A1 (en) 2007-07-03 2010-04-14 Synthon B.V. Tolterodine bead
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
US9561015B2 (en) * 2007-08-24 2017-02-07 General Electric Company Method and apparatus for voice recording with ultrasound imaging
EP2205279B1 (en) 2007-09-28 2011-04-13 Novartis AG Pharmaceutical combination of aliskiren and valsartan
WO2009057138A2 (en) 2007-10-29 2009-05-07 Lupin Limited Controlled release pharmaceutical compositions of tolterodine
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090247628A1 (en) * 2008-03-25 2009-10-01 Auspex Pharmaceuticals, Inc. Substituted phenylcyclohexylglycolates
CN102939008A (en) 2010-04-01 2013-02-20 塞拉维达公司 Methods of improving quality of sleep
RU2671575C2 (en) 2011-05-10 2018-11-02 Теравида, Инк. Appliance of solifenacin and saliva flow stimulators for the treatment of overactive bladder
US20120289560A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
US20140037713A1 (en) * 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
JP2015533174A (en) 2012-10-11 2015-11-19 セラヴィダ，インコーポレイテッド Pharmaceutical formulation of pilocarpine
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110244051A1 (en) * 2010-04-01 2011-10-06 Theravida, Inc. Pharmaceutical formulations for the treatment of overactive bladder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "ACTRN12615000873527: A Phase 2a Study Evaluating the Safety and Efficacy of THVD-102, a combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis", 21 August 2015 (2015-08-21), XP055608561, Retrieved from the Internet <URL:https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368936&isReview=true> [retrieved on 20190724] *

Also Published As

Publication number Publication date
KR20230021184A (en) 2023-02-13
HK1258825A1 (en) 2019-11-22
MX394356B (en) 2025-03-24
US20200188360A1 (en) 2020-06-18
CN108697688A (en) 2018-10-23
AU2022206709A1 (en) 2022-08-11
EP3405191B1 (en) 2025-02-19
RU2018128047A (en) 2020-02-20
CA3011683C (en) 2023-09-26
US20170202778A1 (en) 2017-07-20
AU2016388308B2 (en) 2022-08-04
KR102600541B1 (en) 2023-11-08
RU2718906C2 (en) 2020-04-15
RU2018128047A3 (en) 2020-02-20
TWI810150B (en) 2023-08-01
MX2018008694A (en) 2019-05-15
TW201737906A (en) 2017-11-01
US20220047558A1 (en) 2022-02-17
EP3405191A1 (en) 2018-11-28
CA3011683A1 (en) 2017-07-27
JP6841834B2 (en) 2021-03-10
US11779569B2 (en) 2023-10-10
KR20180102649A (en) 2018-09-17
BR112018014661A2 (en) 2018-12-11
ZA201805490B (en) 2019-11-27
US10328057B2 (en) 2019-06-25
DK3405191T3 (en) 2025-05-19
JP2019506401A (en) 2019-03-07
TW202341976A (en) 2023-11-01
US20190307727A1 (en) 2019-10-10
WO2017127073A1 (en) 2017-07-27
US10610519B2 (en) 2020-04-07
US11185533B2 (en) 2021-11-30
AU2016388308A1 (en) 2018-08-02
KR102495757B1 (en) 2023-02-06

Similar Documents

Publication Publication Date Title
EP3405191A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERHIDROSIS
EP3448398A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
EP3458079A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACNE
EP3541408A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS
EP3302379A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PTÉRYGION
EP3298140A4 (en) COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CALCIFICATION STATES, AND METHODS USING THE SAME
EP3390642A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PIGMENT RETINITY 18 AND PIGMENT RETINITY 13
EP3634431A4 (en) COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF HEPATITIS B
EP3462883A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
MA49576A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS
EP3681498A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3400008A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B
EP3368048A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DOSE
EP3688023A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3638293A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3522865A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF STRETCH MARKS
EP3373951A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF BULLETIN EPIDERMOLYSIS
EP3801478A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CALCIPHYLAXIS
EP3365014A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC MASTOCYTOSIS
EP3638270A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING HYPERTHERMIA TREATMENT
EP3373922A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HOMOCYSTINURIA
EP3452044A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
MA41629A (en) COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
EP3518951A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORTHOPEDIC CONDITIONS
EP3519592A4 (en) MATERIALS AND METHODS FOR THE ASSESSMENT AND TREATMENT OF CANCER

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031410000

Ipc: A61K0009160000

A4 Supplementary search report drawn up and despatched

Effective date: 20190801

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4178 20060101ALI20190726BHEP

Ipc: A61K 9/16 20060101AFI20190726BHEP

Ipc: A61K 9/50 20060101ALI20190726BHEP

Ipc: A61K 31/216 20060101ALI20190726BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1258825

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THERAVIDA, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210222

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230529

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009160000

Ipc: A61K0009500000

Ref document number: 602016091311

Country of ref document: DE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240917

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20240909BHEP

Ipc: A61P 25/02 20060101ALI20240909BHEP

Ipc: A61K 31/216 20060101ALI20240909BHEP

Ipc: A61K 31/4178 20060101ALI20240909BHEP

Ipc: A61K 9/16 20060101ALI20240909BHEP

Ipc: A61K 9/50 20060101AFI20240909BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016091311

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20250514

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250619

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250620

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250520

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1258825

Country of ref document: HK

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1767646

Country of ref document: AT

Kind code of ref document: T

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250219

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016091311

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251222

Year of fee payment: 11

26N No opposition filed

Effective date: 20251120

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20251230

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20260106

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251224

Year of fee payment: 11

Ref country code: NO

Payment date: 20260109

Year of fee payment: 11

Ref country code: DK

Payment date: 20260113

Year of fee payment: 11